Abstract
On average, more than two new species of human virus are reported every year. We constructed the cumulative species discovery curve for human viruses going back to 1901. We fitted a statistical model to these data; the shape of the curve strongly suggests that the process of virus discovery is far from complete. We generated a 95% credible interval for the pool of as yet undiscovered virus species of 38–562. We extrapolated the curve and generated an estimate of 10–40 new species to be discovered by 2020. Although we cannot predict the level of health threat that these new viruses will present, we conclude that novel virus species must be anticipated in public health planning. More systematic virus discovery programmes, covering both humans and potential animal reservoirs of human viruses, should be considered.
1. Introduction
Despite long-standing interest in global biodiversity (May 1988), only recently has the diversity of human pathogens been catalogued (Taylor et al. 2001). Approximately 1400 pathogen species are currently recognized (Woolhouse & Gaunt 2007). Fewer than 200 of these are viruses, but novel virus species are being reported in humans at a rate of over two per year, much faster than for other kinds of pathogen (Woolhouse & Gaunt 2007). Novel viruses are a major public health concern, whether causing disease on the massive scale of HIV/AIDS, more transient events such as the SARS epidemic or potential future threats such as pandemic influenza. An analysis of temporal patterns of virus discovery is therefore of considerable interest.
Our analysis is based on the rate of accumulation of new human virus species: the ‘discovery curve’. Discovery curves have previously been used to estimate the total diversity of various plant and animal taxa (Dove & Cribb 2006; Bebber et al. 2007). However, to our knowledge, the discovery curves have not previously been compiled for any category of human pathogen. Having compiled the discovery curve, we proceed to develop a simple statistical model which we use to estimate the size of the pool of human virus species, N, and the expected rate of discovery of new species to 2020.
2. Material and methods
A standard method for estimating numbers of species is to extrapolate the cumulative species discovery curve (Bebber et al. 2007). We gathered data for this curve by systematically searching the primary literature for first reports of human infection with each of the currently recognized virus species, using species as defined by the International Committee on Taxonomy of Viruses (ICTV; http://www.ictvonline.org/). We note that the set of viruses we are interested in—those that can infect humans—is a small subset of the total (over 1500 species according to ICTV) and, as is discussed below, not a closed set because many of these viruses can also infect other hosts (Taylor et al. 2001). We regard this as analogous to constructing species discovery curves for any subdivision of geographical range or habitat. As we demonstrate below, this approach yields an excellent description of the discovery curve.
We used piecewise linear regression to test for changes in the slope of the discovery curve. The results suggested upswings in 1930 (95% CI, 1929–1933) and 1954 (1953–1956). We therefore restricted detailed analysis to the period 1954–2006.
We modelled discovery since 1954 assuming a total number of species available to be discovered (the species pool) of N virus species, each discovered in any given year with probability p. The model was fitted to the data and assessed using Markov chain Monte Carlo (MCMC)-based Bayesian inference, generating distributions and credible intervals for the parameters. The model defines the expected number of discovered viruses in year t as
The binomial distribution B(N, p) can be accurately approximated by a Poisson distribution with parameter Np for the range of values of N and p of interest. We considered fitting a distribution for values of p; however, provided individual p-values are low there is minimal improvement in model fit. Thus, for a set of model parameters, the likelihood of observing data, X={xi}, the number of viruses discovered for years 1 to k, is given by
We compared the model with the observed data by calculating the mean, trend in the mean and variance for the number of virus species discovered per year (based on five million simulations using best-fit parameter values). The model was extrapolated to year 2020 by calculating the expected number of viruses discovered using the best-fit model. The 95% posterior prediction intervals were calculated using two million model simulations taking into account parameter uncertainty (as given by data from 1954 to 2006) and natural model simulation stochasticity.
As a validation exercise, the model was also fitted to the curve for accumulated virus families from 1954 using the same methods, except that the Poisson approximation no longer holds, so a binomial distribution was used. A family (based on current ICTV classifications) was added to the total when the first post-1954 species was allocated to that family. We tested the assumption that species can be randomly assigned to families (weighted by the size of the families) by noting the number of years in which 0, 1, 2, etc. virus families were discovered. This was done one million times to obtain a distribution for comparison with the observed values.
3. Results
From a comprehensive search of the primary literature, we found 188 virus species that have been reported to infect humans, going back to yellow fever virus in 1901 (table 1). Since then, the number of human virus species discovered in any given year has ranged from zero to six. As is typical (Bebber et al. 2007), the cumulative species discovery curve increases slowly initially and then more rapidly (figure 1). Piecewise linear regression suggests no further upswings since 1954, roughly corresponding to the advent of tissue culture techniques for virus detection (figure 1).
year | species | family |
---|---|---|
1901 | Yellow fever virus | flavi |
1903 | Rabies virus | rhabdo |
1907 | Dengue virus | flavi |
1907 | Human papillomavirus | papilloma |
1907 | Molluscum contagiosum virus | pox |
1907 | Variola virus | pox |
1909 | Poliovirus | picorna |
1911 | Measles virus | paramyxo |
1919 | Human herpesvirus 3 | herpes |
1921 | Human herpesvirus 1 | herpes |
1931 | Rift Valley fever virus | bunya |
1933 | Influenza A virus | orthomyxo |
1933 | Lymphocytic choriomeningitis virus | arena |
1933 | St Louis encephalitis virus | flavi |
1934 | Cercopithecine herpes virus 1 | herpes |
1934 | Japanese encephalitis virus | flavi |
1934 | Louping ill virus | flavi |
1934 | Mumps virus | paramyxo |
1934 | Orf virus | pox |
1937 | Tick-borne encephalitis virus | flavi |
1938 | Cowpox virus | pox |
1938 | Eastern equine encephalitis virus | toga |
1938 | Rubella virus | toga |
1938 | Venezuelan equine encephalitis virus | toga |
1938 | Western equine encephalitis virus | toga |
1940 | Influenza B virus | orthomyxo |
1940 | West Nile virus | flavi |
1941 | Bwamba virus | bunya |
1943 | Newcastle disease virus | paramyxo |
1944 | Sandfly fever Naples virus | bunya |
1944 | Sandfly fever Sicilian virus | bunya |
1946 | Colorado tick fever virus | reo |
1947 | Omsk haemorrhagic fever virus | flavi |
1948 | Encephalomyocarditis virus | picorna |
1948 | Human enterovirus C | picorna |
1949 | Human enterovirus A | picorna |
1949 | Human enterovirus B | picorna |
1950 | Influenza C virus | orthomyxo |
1950 | Vesicular stomatitis virus | rhabdo |
1951 | Bunyamwera virus | bunya |
1952 | California encephalitis virus | bunya |
1952 | Murray Valley encephalitis virus | flavi |
1952 | Ntaya virus | flavi |
1953 | Human rhinovirus A | picorna |
1954 | Human adenovirus B | adeno |
1954 | Human adenovirus C | adeno |
1954 | Human adenovirus E | adeno |
1955 | Human adenovirus D | adeno |
1956 | Chikungunya virus | toga |
1956 | Human herpesvirus 5 | herpes |
1956 | Human parainfluenza virus 2 | paramyxo |
1956 | Ilheus virus | flavi |
1957 | Human adenovirus A | adeno |
1957 | Human respiratory syncytial virus | paramyxo |
1957 | Kyasanur forest disease virus | flavi |
1957 | Mayaro virus | toga |
1957 | Wesselsbron virus | flavi |
1958 | Human parainfluenza virus 1 | paramyxo |
1958 | Human parainfluenza virus 3 | paramyxo |
1958 | Human parechovirus | picorna |
1958 | Junin virus | arena |
1959 | Banzi virus | flavi |
1959 | Guaroa virus | bunya |
1959 | Powassan virus | flavi |
1960 | Human parainfluenza virus 4 | paramyxo |
1960 | Human rhinovirus B | picorna |
1961 | Caraparu virus | bunya |
1961 | Catu virus | bunya |
1961 | O'nyong-nyong virus | toga |
1961 | Oropouche virus | bunya |
1962 | Rio Bravo virus | flavi |
1962 | Sindbis virus | toga |
1963 | Equine rhinitis virus A | picorna |
1963 | Great Island virus | reo |
1963 | Pseudocowpox virus | pox |
1963 | Yaba monkey tumour virus | pox |
1964 | Human herpesvirus 4 | herpes |
1964 | Machupo virus | arena |
1964 | Zika virus | flavi |
1965 | Chagres virus | bunya |
1965 | Foot and mouth disease virus | picorna |
1965 | Tanapox virus | pox |
1965 | Wyeomyia virus | bunya |
1966 | Changuinola virus | reo |
1966 | Human coronavirus 229E | corona |
1966 | Quaranfil virus | unassigned |
1966 | Saimiriine herpesvirus 1 | herpes |
1967 | Chandipura virus | rhabdo |
1967 | Crimean-Congo haemorrhagic fever virus | bunya |
1967 | Human coronavirus OC43 | corona |
1967 | Human enterovirus D | picorna |
1967 | Piry virus | rhabdo |
1967 | Tacaiuma virus | bunya |
1968 | Human herpesvirus 2 | herpes |
1968 | Marburg virus | filo |
1968 | Tataguine virus | bunya |
1970 | Everglades virus | toga |
1970 | Hepatitis B virus | hepadna |
1970 | Lassa virus | arena |
1970 | Punta Toro virus | bunya |
1971 | Aroa virus | flavi |
1971 | BK virus | polyoma |
1971 | Duvenhage virus | rhabdo |
1971 | JC virus | polyoma |
1971 | Vaccinia virus | pox |
1972 | Bovine papular stomatitis virus | pox |
1972 | Mokola virus | rhabdo |
1972 | Monkeypox virus | pox |
1972 | Norwalk virus | calici |
1972 | Ross River virus | toga |
1973 | Bangui virus | bunya |
1973 | Dugbe virus | bunya |
1973 | Hepatitis A virus | picorna |
1973 | Kotonkan virus | rhabdo |
1973 | Rotavirus A | reo |
1973 | Tamdy virus | bunya |
1974 | Getah virus | toga |
1975 | B19 virus | parvo |
1975 | Bhanja virus | bunya |
1975 | Human astrovirus | astro |
1975 | Lebombo virus | reo |
1975 | Shuni virus | bunya |
1975 | Thogoto virus | orthomyxo |
1976 | Orungo virus | reo |
1976 | Wanowrie virus | bunya |
1977 | Hepatitis delta virus | unassigned |
1977 | Sudan Ebola virus | filo |
1977 | Zaire Ebola virus | filo |
1978 | Hantaan virus | bunya |
1978 | Issyk-Kul virus | bunya |
1980 | Human T-lymphotropic virus 1 | retro |
1980 | Puumala virus | bunya |
1982 | Human T-lymphotropic virus 2 | retro |
1982 | Seoul virus | bunya |
1983 | Candiru virus | bunya |
1983 | Hepatitis E virus | unassigned |
1983 | Human adenovirus F | adeno |
1983 | Human immunodeficiency virus 1 | retro |
1984 | Human torovirus | corona |
1984 | Rotavirus B | reo |
1985 | Borna disease virus | borna |
1986 | European bat lyssavirus 2 | rhabdo |
1986 | Human herpesvirus 6 | herpes |
1986 | Human immunodeficiency virus 2 | retro |
1986 | Kasokero virus | bunya |
1986 | Kokobera virus | flavi |
1986 | Rotavirus C | reo |
1987 | Dhori virus | orthomyxo |
1987 | Sealpox virus | pox |
1987 | Suid herpesvirus 1 | herpes |
1988 | Barmah Forest virus | toga |
1988 | Picobirnavirus | birna |
1989 | European bat lyssavirus 1 | rhabdo |
1989 | Hepatitis C virus | flavi |
1990 | Banna virus | reo |
1990 | Gan Gan virus | bunya |
1990 | Reston Ebola virus | filo |
1990 | Semliki Forest virus | toga |
1990 | Trubanaman virus | bunya |
1991 | Guanarito virus | arena |
1992 | Dobrava-Belgrade virus | bunya |
1993 | Sin Nombre virus | bunya |
1994 | Hendra virus | paramyxo |
1994 | Human herpesvirus 7 | herpes |
1994 | Human herpesvirus 8 | herpes |
1994 | Sabia virus | arena |
1995 | Bayou virus | bunya |
1995 | Black Creek Canal virus | bunya |
1995 | Cote d'Ivoire Ebola virus | filo |
1995 | Hepatitis G virus | flavi |
1995 | New York virus | bunya |
1996 | Andes virus | bunya |
1996 | Australian bat lyssavirus | rhabdo |
1996 | Juquitiba virus | bunya |
1996 | Usutu virus | flavi |
1997 | Laguna Negra virus | bunya |
1998 | Menangle virus | paramyxo |
1999 | Nipah virus | paramyxo |
1999 | Torque teno virus | circo |
2000 | Whitewater Arroyo virus | arena |
2001 | Baboon cytomegalovirus | herpes |
2001 | Human metapneumovirus | paramyxo |
2003 | SARS coronavirus | corona |
2004 | Human coronavirus NL63 | corona |
2005 | Human bocavirus | parvo |
2005 | Human coronavirus HKU1 | corona |
2005 | Human T-lymphotropic virus 3 | retro |
2005 | Human T-lymphotropic virus 4 | retro |
We confirmed that our model reproduced the observed slight downward trend in the rate of discovery since 1954 (figure 1) and the observed variance in the data from 1954 to 2006 (figure 2). The distribution of the number of virus species discovered per year shows slight overdispersion (mean=2.69; variance=3.07; variance-to-mean ratio greater than 1) which falls within the predicted range (mean=2.70 with 95% credible interval 2.41–3.00; variance=3.03 with interval 1.99–4.49). Together, these results support our choice of model, even though we do not explicitly consider heterogeneity in the probability of discovering a given species in any one year (p) or temporal variation in sampling effort, detection techniques and reporting.
Noting that p and N are highly correlated (figure 3), our best estimate for p is 0.015 (95% credible interval, 0.004–0.026) with 117 (38–562) so far undiscovered virus species. Extrapolating the discovery curve, allowing for parameter uncertainty and stochastic discovery, we obtain a best estimate of 22 new species (10–40) by 2020 (figure 1).
Data on the cumulative discovery of new virus families are also reproducible (figure 4). The predicted distribution of the number of virus families discovered per year (assuming random allocation of species to families) compares favourably with the observed distribution (figure 5). This provides further support for the appropriateness of our model.
4. Discussion
We conclude that it is extremely probable that new human viruses will continue to be discovered in the immediate future; we are not yet close to the end of the virus discovery curve. As a direct result of this, it is not possible to estimate the size of the species pool for human viruses with precision. However, in contrast to the negative assessment by Bebber et al. (2007) of the use of incomplete species accumulation curves, we consider that the upper and lower limits to our estimate of the size of the species pool are of interest and also have practical implications.
Current trends are consistent with a pool of at least 38 undiscovered species that will be reported at an average rate of at least approximately one per year to 2020. In this context, it is worth noting that three new species were reported in 2007: two polyoma viruses, Ki and Wu, and a reovirus, Melaka (Allander et al. 2007; Chua et al. 2007; Gaynor et al. 2007). Other viruses may have been reported but not yet classified. In practice, future rates of discovery will, of course, be affected by any major advances in virus detection technology or by any major shifts (upwards or downwards) in the effort expended on virus discovery programmes. Tissue culture was regarded as the ‘gold standard’ for virus detection up until a few years ago when molecular methods came to the fore (Storch 2007), although there has not been a detectable increase in discovery rates as a result. Indeed, it is striking that there have been no dramatic changes in the pattern of virus discovery for over 50 years; extrapolations from our data should therefore provide a useful benchmark for probable future discovery rates.
The upper limit for N is finite but large; we cannot rule out hundreds of novel human viruses to be reported in the future. There are two (not mutually exclusive) possible explanations for such a high level of diversity. First, it could reflect the largely unknown extant diversity of viruses in the non-human animal reservoirs that constitute the major source of emerging human pathogens (Taylor et al. 2001; Woolhouse & Gaunt 2007). The majority of human viruses are known to be capable of infecting non-human hosts (almost exclusively mammals and birds), and the animal origin of many apparently novel human viruses (e.g. HIV1 and HIV2, SARS CoV, Nipah virus) has been frequently remarked upon (Morse 1995; Woolhouse & Gowtage-Sequeria 2005; Wolfe et al. 2007); indeed, recently discovered viruses are even more likely to be associated with a non-human reservoir (Woolhouse & Gaunt 2007). All these observations are consistent with the idea that a significant fraction of viruses discovered in the last few decades is ecological ‘spillover’ from animal populations rather than newly evolved specialist human viruses. We have very limited knowledge of the diversity of viruses present in most mammal and bird species (with most attention having been paid to viruses of domestic animals; Cleaveland et al. 2001), so it is unclear for how long this process might continue.
An alternative explanation for a large pool of human viruses is that this reflects a high rate of evolution (within a reservoir population) of truly novel species capable of infecting humans. This hypothesis is difficult to test directly without much more comprehensive sequence data from both human and non-human virus populations. We note that the finite upper limit for the current estimate of N does not necessarily imply that the process of virus discovery is not open-ended (as a result of the evolution of new species) since there could be a low background rate of virus evolution, which will remain once extant diversity has been fully revealed. The balance between revealing extant diversity and the continual evolution of new species could be explored using a more complex model than equation (2.1); however, the available data are insufficient to yield useful estimates of the additional parameters required.
Although we cannot know in advance how big a threat they will pose, novel human viruses must be anticipated in public health planning and surveillance programmes for emerging infectious diseases (King et al. 2006; Jones et al. 2008). However, current approaches to virus discovery are largely passive, usually relying on investigation of reports of human disease with unfamiliar clinical symptoms and uncertain aetiology. Recently, there have been calls for more active discovery programmes for viruses and other pathogens involving ‘systematic sampling and phylogeographic analysis of related pathogens in diverse animal species’ (Wolfe et al. 2007). We consider that such calls are supported by the results reported here.
We are grateful for the support from the Wellcome Trust (M.W., N.S.), the BBSRC (R.H., E.G.) and DEFRA/SFC (L.R., M.C.T.).
References
Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Petersson M.A.A, Dalianis T, Ramquist T& Andersson B . 2007 Identification of a third human polyoma virus. J. Virol. 81, 4130–4136.doi:10.1128/JVI.00028-07. . Crossref, PubMed, Web of Science, Google ScholarBebber D.P, Marriot F.H.C, Gaston K.J, Harris S.A& Scotland R.W . 2007 Predicting unknown species numbers using discovery curves. Proc. R. Soc. B. 274, 1651–1658.doi:10.1098/rspb.2007.0464. . Link, Web of Science, Google ScholarChua K.B, 2007 A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc. Natl Acad. Sci. USA. 104, 11 424–11 429.doi:10.1073/pnas.0701372104. . Crossref, Web of Science, Google ScholarCleaveland S, Laurenson M.K& Taylor L.H . 2001 Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Phil. Trans. R. Soc. B. 356, 991–999.doi:10.1098/rstb.2001.0889. . Link, Web of Science, Google ScholarDove A.D.M& Cribb T.H . 2006 Species accumulation curves and their applications in parasite ecology. Trends Parasitol. 22, 568–574.doi:10.1016/j.pt.2006.09.008. . Crossref, PubMed, Web of Science, Google ScholarGaynor A.M, 2007 Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 3, 595–604.doi:10.1371/journal.ppat.0030064. . Crossref, Web of Science, Google ScholarJones K.E, Patel N.G, Levy M.A, Storeygard A, Balk D, Gittleman J.L& Daszak P . 2008 Global trends in emerging infectious diseases. Nature. 451, 990–993.doi:10.1038/nature06536. . Crossref, PubMed, Web of Science, Google ScholarKing D.A, Peckham C, Waage J.K, Brownlie J& Woolhouse M.E.J . 2006 Infectious diseases: preparing for the future. Science. 313, 1392–1393.doi:10.1126/science.1129134. . Crossref, PubMed, Web of Science, Google ScholarMay R.M . 1988 How many species are there on earth?. Science. 241, 1441–1449.doi:10.1126/science.241.4872.1441. . Crossref, PubMed, Web of Science, Google ScholarMorse S.S . 1995 Factors in the emergence of infectious diseases. Emerg. Infect. Dis. 1, 7–15. Crossref, PubMed, Web of Science, Google Scholar- Storch, G. A. 2007 Diagnostic virology. In Fields virology (eds B. N. Fields, D. M. Knipe & P. M. Howley), pp. 565–604, 5th edn. Philadelphia, PA: Lippincott, Williams & Wilkins. Google Scholar
Taylor L.H, Latham S.M& Woolhouse M.E.J . 2001 Risk factors for human disease emergence. Phil. Trans. R. Soc. B. 356, 983–989.doi:10.1098/rstb.2001.0888. . Link, Web of Science, Google ScholarWolfe N.D, Dunavan C.P& Diamond J . 2007 Origins of major human infectious diseases. Nature. 447, 279–283.doi:10.1038/nature05775. . Crossref, PubMed, Web of Science, Google ScholarWoolhouse M.E.J& Gaunt E . 2007 Ecological origins of novel human pathogens. Crit. Rev. Microbiol. 33, 1–12.doi:10.1080/10408410701647560. . Crossref, PubMed, Web of Science, Google ScholarWoolhouse M.E.J& Gowtage-Sequeria S . 2005 Host range and emerging and re-emerging pathogens. Emerg. Infect. Dis. 11, 1842–1847. Crossref, PubMed, Web of Science, Google Scholar